NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis

Recursion Pharmaceuticals, Inc. (RXRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RXRX

$3.63

+$0.19 (+5.52%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RXRX with… →

RXRX Key Statistics

As of Sep 4, 2026
Trading
Open
$3.42
Previous Close
$3.44
Day's Range
3.41–3.70
52-Week Range
2.77–7.18
Volume
29.01M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.07
Valuation
Market Cap
$1.95B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
35.49
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.06
Financials (FY)
Revenue (FY)
$74.26M+26.96%
Net Income (FY)
−$644.76M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
535.34M
1-Year Return
−19.69%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
19.08M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RXRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−11.25%
2025−39.50%
2024−31.44%
2023+27.89%
2022−54.99%
2021 (partial year)−45.27%

As of September 4, 2026.

RXRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$74.26M−$644.76M−868.3%
2024$58.49M−$463.66M−792.7%
2023$43.88M−$328.07M−747.7%
2022$39.68M−$239.48M−603.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$74.26M$3.30M−$648.13M−$644.76M−868.3%
2024$58.49M$13.25M−$479.00M−$463.66M−792.7%
2023$43.88M$1.29M−$350.06M−$328.07M−747.7%
2022$39.68M−$8.59M−$245.73M−$239.48M−603.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RXRX Valuation vs Biotechnology Median

Median of 656 stocks
MetricRXRXBiotechnology medianvs median
P/S ratio35.4915.26132% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Recursion Pharmaceuticals, Inc. (RXRX) is capitalised at $1.95B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 600 employees.

The most recent close on file for RXRX is $3.63, dated September 4, 2026. That is +$0.19 (+5.52%) against the previous close. Over the past 52 weeks the price has ranged from $2.77 to $7.18. The latest close sits 31.05% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $74.26M. That is +26.96% against the prior fiscal year, when revenue was $58.49M. The same year closed with a net loss of $644.76M. Profit margin runs at 0%. Trailing earnings per share are −1.06.

Across the 4 fiscal years on file, revenue moves from $39.68M in 2022 to $74.26M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 35.49. On price-to-sales that is 132.49% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.07. Annualized volatility over the trailing 5 years is 93.01%. Over the trailing twelve months the price has returned −19.69%. Measured over 5 years, that is −33.06% a year compounded.

Growth & Income

No dividend is on file for RXRX.

So far in 2026 the price is −11.25%. The strongest complete calendar year on file is 2023 at +27.89%; the weakest is 2022 at −54.99%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Recursion Pharmaceuticals, Inc. (RXRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Recursion Pharmaceuticals, Inc. RXRX $1.95B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Recursion Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Visit website →